CN101496585A - 欧米加3复合食品补充剂 - Google Patents
欧米加3复合食品补充剂 Download PDFInfo
- Publication number
- CN101496585A CN101496585A CNA2008100333837A CN200810033383A CN101496585A CN 101496585 A CN101496585 A CN 101496585A CN A2008100333837 A CNA2008100333837 A CN A2008100333837A CN 200810033383 A CN200810033383 A CN 200810033383A CN 101496585 A CN101496585 A CN 101496585A
- Authority
- CN
- China
- Prior art keywords
- omega
- percent
- vitamin
- lecithin
- food supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002131 composite material Substances 0.000 title abstract 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 26
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 235000010445 lecithin Nutrition 0.000 claims abstract description 23
- 229940067606 lecithin Drugs 0.000 claims abstract description 23
- 239000000787 lecithin Substances 0.000 claims abstract description 23
- 229940046009 vitamin E Drugs 0.000 claims abstract description 23
- 239000011709 vitamin E Substances 0.000 claims abstract description 23
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 21
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 21
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 21
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 22
- 235000020778 linoleic acid Nutrition 0.000 claims description 22
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 22
- 241000229143 Hippophae Species 0.000 claims description 18
- 229930003944 flavone Natural products 0.000 claims description 12
- 235000011949 flavones Nutrition 0.000 claims description 12
- 150000002213 flavones Chemical class 0.000 claims description 11
- 239000000470 constituent Substances 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 abstract description 22
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 14
- 241000196324 Embryophyta Species 0.000 abstract description 10
- 235000015872 dietary supplement Nutrition 0.000 abstract description 7
- 235000019197 fats Nutrition 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 241000721047 Danaus plexippus Species 0.000 abstract description 4
- 238000012545 processing Methods 0.000 abstract description 4
- 240000000950 Hippophae rhamnoides Species 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 125000001931 aliphatic group Chemical group 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 206010039966 Senile dementia Diseases 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- UCZJPQIEFFTIEV-UHFFFAOYSA-N 5-methoxy-6-methyl-2-phenylchromen-7-one Chemical compound C=1C=C2C(OC)=C(C)C(=O)C=C2OC=1C1=CC=CC=C1 UCZJPQIEFFTIEV-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 241000219193 Brassicaceae Species 0.000 description 2
- 241000931705 Cicada Species 0.000 description 2
- 241001251068 Formica fusca Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000361919 Metaphire sieboldi Species 0.000 description 2
- 241000382353 Pupa Species 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- -1 linoleic acid, leukotrienes Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000011305 Capsella bursa pastoris Nutrition 0.000 description 1
- 240000008867 Capsella bursa-pastoris Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000004481 Choline Deficiency Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 244000236527 Linum perenne Species 0.000 description 1
- 235000008569 Linum perenne Nutrition 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000021752 choline deficiency disease Diseases 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 235000019508 mustard seed Nutrition 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种欧米加3复合食品补充剂。其特征在于由下列组成物及重量百分比组成：植物欧米加3提取物75－94％，沙棘籽提取物3－15％，卵磷脂2－7％，维生素E1－5％。本发明的优点是采用传统中医养生学理论中，君、臣、佐使的方法，进行合理复方组合，既保护了4种不同的物质的天然活性物质，又突出了补充欧米加3的重要性。其中以欧米加3为(君)，75－94％的用量，又以沙棘籽提取物为(臣)，3－15％的用量，弥补了欧米加3(ω－3)中一些成分的缺少。再加以卵磷脂为(佐)2－7％和以维生素E为(使)1－5％的用量，使得这种复合欧米加3食品补充物，既有对人体更均衡的脂肪物质的补充，也增强了人体的吸收与应用。同时，有益于这种复合物较长时间的贮存。因此，增加了此种复合物在食品加工过程中，广泛应用的作用。
Description
技术领域
本发明涉及一种食品补充剂，特别是一种欧米加3复合食品补充剂。
背景技术
欧米加3(ω-3)；亦称：亚麻酸；学名：Alpha-Linolenic Acid，它是一种人体必需的多不饱和脂肪酸，含有DHA(二十二碳六烯酸)、EPA(二十碳五烯酸)等物质，是人类不可缺少，且又不能自身合成，必须从外界摄取，应适时给予补充的脂肪酸类物质。
它可以有效降解体内过量的饱和脂肪酸及血竭素物(即沉积物)，降解低密度胆固醇、高甘油三酯等人体有害病变物质，增加高密度胆固醇和高密度脂蛋白的成份含量，从根本上有效防治高血脂、脂肪肝、心肌梗塞及高血压的发生；有效地抑制血栓形成及化解血栓、修复血栓疤痕、保证血管所需血氧，恢复血管弹性，以达到软化血管，降低血压和血糖，抑制肿瘤的发生和转移，防止动脉硬化的作用。对提高青少年的记忆力和思维能力，预防老年性痴呆症和降低炎症，提高人的眼睛的视敏度等方面，有着其他物质无可替代的作用。研究表明，当人体摄入脂肪酸的比例合适的时候，人的生理特征将达到“最佳状态”。(人体摄入脂肪酸的合适比例为：饱和脂肪酸≤10％；不饱和脂肪酸≥85％。其中单不饱和脂肪酸≥75％，多不饱和脂肪酸中的ω-3≥3％；ω-6≤12％；ω-3与ω-6的比例小于等于1∶4)。否则，将会产生加速人体进入亚健康状态或疾病状态的过程。特别是现在，由于大多数城镇居民无从补充欧米加3，在极度缺少欧米加3脂肪酸时，将会影响大脑细胞及全身细胞的健康生成，加大炎症状态，不利于脂肪的代谢，同时增加患心脑血管疾病、糖尿病、老年痴呆及肿瘤疾病的机率。因此，医学及营养学界，经过20多年的研究，经历了多次有患心脑血管疾病、糖尿病、老年痴呆及肿瘤疾病志愿者参与的双盲试验之后，才最终发现了欧米加3脂肪酸是一种人体必须的，不可缺少的重要脂肪类物质。因此，补充欧米加3脂肪酸是人类的当务之极。
可是，就是这种重要的油状物质，我们人类，特别是现在的城镇居民，几乎在现代食物的生物链中已经很难摄取到了。因为，此类物质只存在于自然界的大黑蚂蚁、蚯蚓、蝗虫、蝉蛹等昆虫的生物体，以及部分野菜、干果、十字花科等植物中。虽然，它同时也存在于人类主要的动物类食品肉食之中，可是由于人类肉食的主要来源---鸡、鸭、猪、鱼等动物，现在大多都是用工业化饲料饲养，它们再也无法接触自然生态，很难吃到存在于自然界的大黑蚂蚁、蚯蚓、蝗虫、蝉蛹等昆虫的生物体，以及部分野菜、干果、十字花科等植物。使自然生态的食物链、生物链断裂，从而让人类，特别是城镇居民严重缺失。
经调查表明，我国13亿人群中，有近10亿人缺少欧米加3脂肪酸，特别是居住在城镇之中的老人、孕妇和儿童严重缺失，是造成我国居民慢性功能性疾病数量不断加大，同时，也是使这类疾病向低令化发展的重要因素。欧、美、日多个实验室研究证明，缺少了欧米加3，是造成现代疾病的一个重要因素之一。因此，补充欧米加3，是对我国人民健康状况的改善，提高人们生命质量的一项刻不容缓的健康大事。
发明内容
本发明的目的，是解决现代人类，由于广泛食用工业化生产饲料所喂养的鸡、鸭、猪、鱼等肉食之后，所存在缺失欧米加3脂肪酸的问题。给人们提供一种欧米加3复合食品补充剂。
成品为半透明油状物或乳白粉末，可应用于各类食品补充添加。在不同的食品加工过程中，如牛奶、面包、饼干及各类面食、油脂制品，可按比例加入。人可按年龄分为中老年人、孕妇、儿童、成人四个系列，并按说明直接口服补充。
本发明设计欧米加3复合食品补充剂，其特征在于由下列组成物及重量百分比组成：植物欧米加3提取物(ω-3含量为≥55g/100g)75-94％，沙棘籽提取物(黄酮含量≥650mg/100g)3-15％，卵磷脂(亚油酸≤100mg/100g)2-7％，维生素E(亚油酸≤100mg/100g)1-5％。
其特征在于由下列组成物及重量百分比组成：植物欧米加3提取物(ω-3含量为≥55g/100g)75％，沙棘籽提取物(黄酮含量≥650mg/100g)15％，卵磷脂(亚油酸≤100mg/100g)5％，维生素E(亚油酸≤100mg/100g)5％。
其特征在于由下列组成物及重量百分比组成：植物欧米加3提取物(ω-3含量为≥55g/100g)94％，沙棘籽提取物(黄酮含量≥650mg/100g)3％，卵磷脂(亚油酸≤100mg/100g)2％，维生素E(亚油酸≤100mg/100g)1％。
其特征在于由下列组成物及重量百分比组成：植物欧米加3提取物(ω-3含量为≥55g/100g)85％，沙棘籽提取物(黄酮含量≥650mg/100g)10％，卵磷脂(亚油酸≤100mg/100g)4％，维生素E(亚油酸≤100mg/100g)1％。
本发明的优点是采用传统中医养生学理论中，君、臣、佐使的方法，进行合理复方组合，即保护了4种不同的物质的天然活性物质，又突出了补充欧米加3(ω-3)的重要性。其中以欧米加3(ω-3)为(君)，75-94％的用量，又以沙棘籽提取物为(臣)，3-15％的用量，弥补了欧米加3(ω-3)中一些成分的缺少。再加以卵磷脂为(佐)2-7％和以维生素E为(使)1-5％的用量，使得这种复合欧米加3食品补充物，即有对人体更均衡的脂肪物质的补充，也增强了人体的吸收与应用。同时，有益于这种复合物较长时间的贮存。因此，增加了此种复合物在食品加工过程中，广泛应用的作用。
下面结合实例对本发明作详细说明。
具体实施方式
实施例1：
将植物欧米加3提取物(ω-3含量为≥55g/100g)75千克，沙棘籽提取物(黄酮含量≥650mg/100g)15千克，卵磷脂(亚油酸≤100mg/100g)5千克，维生素E(亚油酸≤100mg/100g)5千克，在符合食品卫生的常温环境下，经3—5分钟均匀轻柔的搅拌后，即可包装出成品。
实施例2：
植物欧米加3提取物(ω-3含量为≥55g/100g)94千克，沙棘籽提取物(黄酮含量≥650mg/100g)3千克，卵磷脂(亚油酸≤100mg/100g)2千克，维生素E(亚油酸≤100mg/100g)1千克。在符合食品卫生的常温环境下，经3—5分钟均匀轻柔的搅拌后，即可包装出成品。
实施例3：
植物欧米加3提取物(ω-3含量为≥55g/100g)85千克，沙棘籽提取物(黄酮含量≥650mg/100g)10千克，卵磷脂(亚油酸≤100mg/100g)4千克，维生素E(亚油酸≤100mg/100g)1千克。在符合食品卫生的常温环境下，经3—5分钟均匀轻柔的搅拌后，即可包装出成品。
成品按计量和包装，可分为中老年人、孕妇、儿童、成人四个系列，届时人们可按说明直接口服补充。在不同的食品加工过程中，如牛奶、面包、饼干及各类面食、油脂制品，可按比例添加。该产品为半透明油状物或乳白粉末(若用沙棘果油将略呈浑浊状)，纯植物脂类物质，清香无鱼腥味，不含胆固醇。
补充剂中的四种成份的主要功能及作用：
欧米加3(ω-3)亚麻酸基本功能主要表现为：
可明显提高青少年的记忆力和思维能力，并有预防老年性痴呆症的发生，预防心脑血管疾病、降低血脂和血压，抑制出血性脑中风、血栓性疾病、癌症的发生和转移，预防人体衰老和过敏反应，预防心肌梗塞和脑梗塞、过敏性疾病、抗炎等作用。采用从野亚麻荠、紫苏及产于加拿大和我国西北的“科罗纳”籽(亦称芥子)，提取的高浓度植物欧米加3(ω-3)，具有工艺简单、技术成熟和稳定，原料广泛，不含胆固醇，国际、国内市场大量有售。
沙棘籽提取物(主要是沙棘籽油或果油)；采用德国CO2超临界提取技术淬取。沙棘中含有丰富的维生素(Ve、Vc、Vp、Vk、VB6、VB12等)，胡萝卜素类(β-胡萝卜素)，不饱和脂肪酸类(亚油酸、亚麻酸、棕榈酸等)，黄酮类(黄酮甙、黄酮甙元、异鼠李素、槲皮素)，微量元素(Fe、Cu、Zn、K、Ca等)氨基酸(天门冬氨酸等十七种人体必须的成份)，有机酸(苹果酸、草酸等)、磷脂类(卵磷脂、脑磷脂、磷脂酰肌醇)以及5-羟色胺、白花青素、香豆素等。含有人体必需的八种氨基酸中的七种(不含色氨酸)，沙棘含有钙、铁、锌、钾、硒等十一种人体必需的微量元素。每100g主要成份中含：总黄酮(以槲皮素计)710mg；总类胡萝卜素≥150mg；胡萝卜素≥5mg；β-维生素E≥100mg；γ-维生素E≥60mg；不饱和脂肪酸含量≥65％；其中ω-3不饱脂肪酸≥28％；不皂化物≥1％。
早在中国藏医药经典著作《四部医典》，就记载了沙棘具有祛痰、利肺、化湿、壮阴、升阳的功能，60余处记载了沙棘健脾养胃、化瘀止血的作用。今天，更被“中国药典”确立了是药食双用的珍贵资源。它抗炎生肌、抑肿瘤、增免疫、抗衰老、抗辐射，对心脑之血管，肠胃之系统大有疗效。
沙棘沙棘籽油或果油在临床上对烧伤、烫伤及宫颈糜烂有显著疗效；对慢性浅表性胃炎、萎缩性胃炎、胃溃疡、十二指肠溃疡、口腔溃疡、久病体虚、老年性体弱等疗效确切；对预防和治疗冠心病、心绞痛、动脉硬化等心脑血管疾病；对人体不同的生理系统能起到均衡营养、调理功能、调节新陈代谢的作用，从而对人体起到全面保健的作用，被国际医药学及营养学专家誉为人类廿一世纪最具发展前途的营养保健及天然医药物品。中国水利部沙棘研究中心大量生产。
卵磷脂和维生素E是常用保健食品，已有广泛应用。
卵磷脂
卵磷脂取之于大豆。大豆则被誉为21世纪的“维生素”。大豆中的主要成分---卵磷脂的诸多保健功能亦逐渐被人们所认识。在美国，国家食品营养学会已正式把胆碱定为每天所必需的营养素，而卵磷脂则是胆碱最好的供体，补充卵磷脂就等于补充了胆碱，这也是卵磷脂为何风靡欧美的主要原因。在美国数千种营养补充剂中，卵磷脂的销售高居排行榜第二位(第一位是维生素类)，它已成为与蛋白质、维生素一样重要的营养素。
它预防脂肪肝及肝硬化的功能显著，磷脂中的胆碱对脂肪有亲和力，若体内胆碱不足，则会影响脂肪代谢，造成脂肪在肝内积聚，形成脂肪肝甚至会发生肝硬化。卵磷脂不但能预防脂肪肝，还能促进肝细胞再生，防止肝硬化，并有助于肝功能的恢复，尤其是对一些因酗酒而引起的肝硬化有明显的效果。
它能够促进神经传导，提高大脑活力，降低血清胆固醇、降低血液粘度、促进血液的循环，预防心血管疾病。磷脂具有使细胞活化，使脑机能活化及预防老年痴呆的功能。磷脂对人的智力发育、记忆力增强有独特作用。磷脂可将屯积于肝脏中的脂肪乳化，以充分保护肝细胞，促进肝细胞的活化和再生，增强肝功能，对防治肝病，特别是脂肪肝功效显著。是常用保健物品。
维生素E
维生素E又名生育酚或产妊酚，维生素E又被广泛用于抗衰老方面，认为它可消除脂褐素在细胞中的沉积，改善细胞的正常功能，减慢组织细胞的衰老过程。维生素E有很强的抗氧化作用，可防止脂肪化合物、维生素A、硒(Se)、两种硫氨基酸和维生素C的氧化作和提高维生素A的作用。维生素E是一种很重要的血管扩张剂和抗凝血剂，能延缓细胞因氧化而老化，保持青春的容姿。能供给体内氧气，使您更有耐久力。和维生素A一起作用，抵御大气污染，保护肺脏，防止血液凝固，减轻疲劳等作用。是常用保健物品。
Claims (4)
1、欧米加3复合食品补充剂，其特征在于由下列组成物及重量百分比组成：
植物欧米加3提取物(ω-3含量为≥55g/100g) 75-94％，
沙棘籽提取物(黄酮含量≥650mg/100g) 3-15％，
卵磷脂(亚油酸≤100mg/100g) 2-7％，
维生素E(亚油酸≤100mg/100g) 1-5％。
2、按权利要求1所述的欧米加3复合食品补充剂，其特征在于由下列组成物及重量百分比组成：
植物欧米加3提取物(ω-3含量为≥55g/100g) 75％，
沙棘籽提取物(黄酮含量≥650mg/100g) 15％，
卵磷脂(亚油酸≤100mg/100g) 5％，
维生素E(亚油酸≤100mg/100g) 5％。
3、按权利要求1所述的欧米加3复合食品补充剂，其特征在于由下列组成物及重量百分比组成：
植物欧米加3提取物(ω-3含量为≥55g/100g) 94％，
沙棘籽提取物(黄酮含量≥650mg/100g) 3％，
卵磷脂(亚油酸≤100mg/100g) 2％，
维生素E(亚油酸≤100mg/100g) 1％。
4、按权利要求1所述的欧米加3复合食品补充剂，其特征在于由下列组成物及重量百分比组成：
植物欧米加3提取物(ω-3含量为≥55g/100g) 85％，
沙棘籽提取物(黄酮含量≥650mg/100g) 10％，
卵磷脂(亚油酸≤100mg/100g) 4％，
维生素E(亚油酸≤100mg/100g) 1％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100333837A CN101496585B (zh) | 2008-01-31 | 2008-01-31 | 欧米加3复合食品补充剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100333837A CN101496585B (zh) | 2008-01-31 | 2008-01-31 | 欧米加3复合食品补充剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101496585A true CN101496585A (zh) | 2009-08-05 |
| CN101496585B CN101496585B (zh) | 2012-11-07 |
Family
ID=40944020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100333837A Active CN101496585B (zh) | 2008-01-31 | 2008-01-31 | 欧米加3复合食品补充剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101496585B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102919385A (zh) * | 2012-11-20 | 2013-02-13 | 曾晓飞 | 一种富含欧米伽3复配食品补充剂的新型食品 |
| CN103766909A (zh) * | 2012-10-17 | 2014-05-07 | 曾晓飞 | 一种富含欧米伽3复配食品补充剂的新型食品 |
| CN104413169A (zh) * | 2013-10-16 | 2015-03-18 | 曾晓飞 | 一种以茶籽油为主,欧米伽3、6、9脂肪酸均衡的营养强化食品 |
| CN104605370A (zh) * | 2015-01-30 | 2015-05-13 | 曾晓飞 | 一种以珊瑚藻为主的富含欧米伽3脂肪酸的营养强化食品 |
| CN112293737A (zh) * | 2020-12-01 | 2021-02-02 | 曾晓飞 | 欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1732916A (zh) * | 2004-08-09 | 2006-02-15 | 李川明 | 含原花青素和其它功能成分的复方医疗保健制剂 |
| CN1321663C (zh) * | 2005-05-11 | 2007-06-20 | 黑龙江九三油脂有限责任公司 | 作为保健食品的沙棘油复合软胶囊 |
-
2008
- 2008-01-31 CN CN2008100333837A patent/CN101496585B/zh active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103766909A (zh) * | 2012-10-17 | 2014-05-07 | 曾晓飞 | 一种富含欧米伽3复配食品补充剂的新型食品 |
| CN102919385A (zh) * | 2012-11-20 | 2013-02-13 | 曾晓飞 | 一种富含欧米伽3复配食品补充剂的新型食品 |
| CN104413169A (zh) * | 2013-10-16 | 2015-03-18 | 曾晓飞 | 一种以茶籽油为主,欧米伽3、6、9脂肪酸均衡的营养强化食品 |
| CN104605370A (zh) * | 2015-01-30 | 2015-05-13 | 曾晓飞 | 一种以珊瑚藻为主的富含欧米伽3脂肪酸的营养强化食品 |
| CN104605370B (zh) * | 2015-01-30 | 2017-03-22 | 曾晓飞 | 一种以珊瑚藻为主的富含欧米伽3脂肪酸的营养强化食品 |
| CN112293737A (zh) * | 2020-12-01 | 2021-02-02 | 曾晓飞 | 欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101496585B (zh) | 2012-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1328966C (zh) | 用于膳食补充物的营养组合物 | |
| Feng et al. | Comparative effects of dietary microalgae oil and fish oil on fatty acid composition and sensory quality of table eggs | |
| JP2004515508A (ja) | 化合物の健康促進組成物 | |
| CN101496585B (zh) | 欧米加3复合食品补充剂 | |
| PT1662904E (pt) | Composições contendo elementos da semente de salvia sclarea como ingrediente activo | |
| JP2014000007A (ja) | カプセル状食品 | |
| CN108703364A (zh) | 脂肪酸代谢异常专用型临床营养配方及其制备方法 | |
| RU2505075C1 (ru) | Питательные композиции, включающие фруктовые хлопья, содержащие докозагексаеновую кислоту | |
| Cofrades et al. | Applications of Seaweed in Meat‐Based Functional Foods | |
| CN101564180B (zh) | 一种核桃全营养素在制备益智和增强免疫力的药品或保健品中的应用 | |
| CN103766909A (zh) | 一种富含欧米伽3复配食品补充剂的新型食品 | |
| CN109965273A (zh) | 一种小儿多动症专用型临床营养配方及其制备方法 | |
| Kanojia | Development of value-added cookies incorporated with Spirulina platensis for the mitigation of malnutrition in children | |
| Moghaddasi | Linseed and usages in Humanlife | |
| Yannakopoulos | Egg enrichment in omega-3 fatty acids | |
| Lee | Essent ial Fat ty Acids | |
| CN103766507A (zh) | 一种具有保健功能的食用油 | |
| CN102763757B (zh) | 一种蓝莓、芹菜复合降压保健软糖的生产方法 | |
| CN1123093A (zh) | 富含ω-3脂肪酸系列保健糖果 | |
| WO2002094039A1 (en) | Food or beverage for ameliorating poor protein/energy nutrition | |
| Mascolo et al. | Nutritional value of fish species | |
| CN108703373A (zh) | 一种七色营养素 | |
| CN1640459A (zh) | 复合大豆营养素及其制剂 | |
| Matran et al. | The role of hemp seed derivatives bakery, related to the ratio of essential polyaunsaturated fatty acids omega 3 and omega 6, cold pressed hemp oil, complete protein and fibres | |
| Doughman et al. | DHA-Rich Algae Oil Is a Safe and Effective Vegetarian Source of Omega-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 200434 room 22, No. 642, Lane 402, North Station Road, Shanghai, Hongkou District Applicant after: Zeng Xiaofei Applicant after: Zheng Shanliang Address before: 200434 room 22, No. 642, Lane 402, North Station Road, Shanghai, Hongkou District Applicant before: Zheng Shanliang Applicant before: Zeng Xiaofei |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ZHENG SHANLIANG TO: CENG XIAOFEI |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Zeng Xiaofei Document name: Notification that Application Deemed not to be Proposed |
|
| DD01 | Delivery of document by public notice | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170912 Address after: 200434 room 22, No. 642, Lane 402, North Station Road, Shanghai, Hongkou District Patentee after: Zeng Xiaofei Address before: 200434 room 22, No. 642, Lane 402, North Station Road, Shanghai, Hongkou District Co-patentee before: Zheng Shanliang Patentee before: Zeng Xiaofei |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170926 Address after: 510000 South Bay 16-1-1603, front Avenue, Nansha District port, Guangdong, Guangzhou Patentee after: Zeng Xiaofei Address before: 200434 room 22, No. 642, Lane 402, North Station Road, Shanghai, Hongkou District Co-patentee before: Zheng Shanliang Patentee before: Zeng Xiaofei |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171122 Address after: 518054 Guangdong city of Shenzhen province Nanshan District Guangdong streets south road to the new apartment 107 ten Wei Patentee after: Shenzhen easy Bioengineering Co.,Ltd. Address before: 510000 South Bay 16-1-1603, front Avenue, Nansha District port, Guangdong, Guangzhou Patentee before: Zeng Xiaofei |
|
| DD01 | Delivery of document by public notice |
Addressee: Liao Zhenzhen Document name: deemed not to have given notice |
|
| DD01 | Delivery of document by public notice | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220902 Address after: Room 203, block 2, building 6, yixinyuan, Xinghewan, No. 521, Yingbin Road, Panyu District, Guangzhou, Guangdong 511400 Patentee after: Zeng Xiaofei Address before: 518054 107 jindiweixin apartment, Gaoxin South 10th Road, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province Patentee before: Shenzhen easy Bioengineering Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| DD01 | Delivery of document by public notice |
Addressee: Liang Jian Document name: Notice of Conformity |
|
| DD01 | Delivery of document by public notice | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230510 Address after: Zone 01, 6th Floor, Shunke Real Estate Building, No. 3 Zhicheng Road, Fengsha Village, Daliang Street, Shunde District, Foshan City, Guangdong Province, 528000 Patentee after: Guangdong Zhaotai Yugong Biotechnology Co.,Ltd. Address before: Room 203, block 2, building 6, yixinyuan, Xinghewan, No. 521, Yingbin Road, Panyu District, Guangzhou, Guangdong 511400 Patentee before: Zeng Xiaofei |
|
| TR01 | Transfer of patent right |